Life Sciences News Feeds

  • Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference5 June 2026, 8:01 pm

    CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practi

  • CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026
    CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 20265 June 2026, 8:00 pm

    SHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data demonstrated robust weight reduction, preservation of lean mass, reduced weight regain following treatment discontinuation and the potential for extended dosing intervals. CC-18 is designed to address a growing challenge in

  • Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity
    Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity5 June 2026, 6:40 pm

    BOULDER, Colo.--(BUSINESS WIRE)-- #AVLaboratories--At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories has been studying skin cells to better understand what supports the visible qualities associated with healthier-looking, more resilient skin over time. While much of the longevity conversation has centered on high-profile molecules associated with NAD+ and “breakthrough” molecules, AV Laboratories’ recent research points back to something more fundamental: amino acids. Wi

  • Feinstein Institutes’ John M. Kane honored with 2026 Schizophrenia International Research Society Lifetime Achievement Award
    Feinstein Institutes’ John M. Kane honored with 2026 Schizophrenia International Research Society Lifetime Achievement Award5 June 2026, 4:00 pm

    MANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society (SIRS). This recognition celebrates his decades-long contributions that have transformed the understanding, treatment and outcomes for individuals living with schizophrenia worldwide. The SIRS Lifetime Achievement Award is one of

  • Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
    Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5 June 2026, 4:00 pm

    BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres

  • IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
    IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia5 June 2026, 3:09 pm

    AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application (MAA) for AQNEURSA® (levacetylleucine) to include the treatment of Ataxia-Telangiectasia (A-T). This submission represents the first regulatory application submitted to the EMA seeking approval of a therapy for the treatment of A-T, a rare, progressive, inherited neurodegenerative disorder. The v

  • Laser Treatments Have Long Excluded Patients with Darker Skin; New Korean Technology Is Changing the Industry
    Laser Treatments Have Long Excluded Patients with Darker Skin; New Korean Technology Is Changing the Industry5 June 2026, 2:26 pm

    PARK CITY, Utah--(BUSINESS WIRE)--In an effort to expand safe and effective treatment options for patients historically underserved by aesthetic lasers, Powered by MRP today announced an exclusive U.S. distribution agreement with South Korean manufacturer Bluecore Company. The partnership brings Bluecore's portfolio of aesthetic laser technologies to the United States, including Picore, a picosecond platform, and Iris Pi, a Q-switched system designed to improve treatment outcomes across a broad

  • LivaNova Appoints Anne Liddy as Chief Legal Officer
    LivaNova Appoints Anne Liddy as Chief Legal Officer5 June 2026, 1:00 pm

    LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNo

  • Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
    Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy5 June 2026, 12:30 pm

    SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes.

  • Glooko Introduces the First and Only Pump Settings EHR Integration to Bring Insulin Pump Data Directly Into Clinical Workflows
    Glooko Introduces the First and Only Pump Settings EHR Integration to Bring Insulin Pump Data Directly Into Clinical Workflows5 June 2026, 12:00 pm

    PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the launch of its Insulin Pump Settings Electronic Health Record (EHR) Integration, a new and first-of-its-kind capability in its latest software release that visualizes critical insulin pump configuration data directly into the clinical workflow. For clinics caring for

  • Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
    Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5 June 2026, 11:00 am

    NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co

  • Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease5 June 2026, 10:40 am

    WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month

  • Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5 June 2026, 10:30 am

    LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of

  • Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
    Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa5 June 2026, 7:00 am

    FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. “South Africa is at the heart of global efforts to end HIV. With the country’s launch of lenacapavir, there is now an opportunity to rapidly accelerate progress,” said Daniel O’Day, Chairma

  • AHF's ‘GOOOOOOOOOAL!’ Billboards Remind World Cup Fans to Score Safely
    AHF's ‘GOOOOOOOOOAL!’ Billboards Remind World Cup Fans to Score Safely4 June 2026, 10:24 pm

    LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's ‘GOOOOOOOOOAL!’ Billboards Remind World Cup Fans to Score Safely

  • Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation
    Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation4 June 2026, 10:06 pm

    HOUSTON--(BUSINESS WIRE)-- #Biotech--Goldenrod Therapeutics, innovator in brain inflammation treatments for neurological conditions, completed initial close on $6.5 million Series Seed.

  • Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
    Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference4 June 2026, 8:30 pm

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio

  • Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings
    Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4 June 2026, 6:15 pm

    BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #DrivenbyPurpose--Vycellix to attend key upcoming investor & partnering events to share progress reports for its allogeneic cancer cell therapy platforms and products.

  • Kalogon Raises $5.75M to Make Sitting Healthier for All
    Kalogon Raises $5.75M to Make Sitting Healthier for All4 June 2026, 1:00 pm

    MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon raises $5.75M led by Enable Ventures to expand smart seating solutions for wheelchair users, aviation and beyond.

  • Humata Health Joins CMS Electronic Prior Authorization Acceleration Initiative to Speed Care for Patients and Providers
    Humata Health Joins CMS Electronic Prior Authorization Acceleration Initiative to Speed Care for Patients and Providers4 June 2026, 1:00 pm

    WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced it has joined the Centers for Medicare and Medicaid Services (CMS) Electronic Prior Authorization Acceleration initiative as a Friend of the Ecosystem. Launched through the CMS Health Tech Ecosystem, it brings together health systems, payers, electronic health record developers, and technology partners to address the workflow, technical, and operational challenges slowing adopt

  • GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities
    GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities4 June 2026, 12:00 pm

    CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control

  • Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting
    Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 12:00 pm

    DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting

  • Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting
    Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 11:00 am

    NEW YORK--(BUSINESS WIRE)--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, the Company presented results from several clinical and preclinical studies that support the initiation of Phase 3 studies of elismetrep, a novel TRPM8 channel blocker. Elismetrep is a potentially new approach for migraine and the only agent known to be in late-stage deve

  • Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
    Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology3 June 2026, 8:30 pm

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology

  • Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients
    Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients3 June 2026, 2:01 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC). The collaboratio

  • HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup
    HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup3 June 2026, 2:00 pm

    NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Riley J. Williams III, MD, as Venue Medical Officer (VMO) for the 2026 World Cup. The New York / New Jersey area will host matches, including the final, taking place in East Rutherford, New Jersey at MetLife Stadium. In this role, Dr. Williams, Chief of the HSS Sports Medicine Institute, Medical D

  • STARLIMS Appoints Max Schultz as Chief Executive Officer
    STARLIMS Appoints Max Schultz as Chief Executive Officer3 June 2026, 1:36 pm

    HOLLYWOOD, Fla.--(BUSINESS WIRE)--STARLIMS, a global leader in enterprise laboratory informatics software, today announced the appointment of Max Schultz as Chief Executive Officer. This leadership transition comes at a time of growth for STARLIMS, with the company accelerating product innovation, expanding its portfolio through strategic acquisitions, and delivering agentic capabilities for enterprise laboratories. As a seasoned enterprise software executive, Schultz brings a strong track reco

  • Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference3 June 2026, 12:01 pm

    BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com

  • Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
    Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 20262 June 2026, 8:01 pm

    FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

  • Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Riva Posterior Fixation System®
    Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Riva Posterior Fixation System®2 June 2026, 5:22 pm

    ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical announces FDA clearance and full commercial launch for its Riva Posterior Fixation System.

  • eternalHealth, Zynix AI, and nirvanaHealth Announce Integrated Partnership to Scale AI-Enabled Care Management and Member Engagement
    eternalHealth, Zynix AI, and nirvanaHealth Announce Integrated Partnership to Scale AI-Enabled Care Management and Member Engagement2 June 2026, 2:00 pm

    BOSTON & TAMPA, Fla.--(BUSINESS WIRE)--eternalHealth, a Medicare Advantage plan serving Medicare beneficiaries in Massachusetts and Arizona, today announced an integrated partnership with Zynix AI, a healthcare AI platform built to operationalize care management, patient engagement, and quality improvement at scale, and nirvanaHealth, a cloud-native enterprise platform supporting pharmacy benefit management, claims adjudication, and centralized healthcare data infrastructure. Since January 1, 2

  • Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay
    Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay2 June 2026, 11:00 am

    GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Annals of Neurology reveals a positive alpha-synuclein (α-synuclein) seed amplification assay (SAA) and the automated imaging differentiation for parkinsonism (AIDP) provide unique information key to understanding Parkinson’s diseas

  • Sarepta Therapeutics to Participate in Upcoming Investor Conferences
    Sarepta Therapeutics to Participate in Upcoming Investor Conferences1 June 2026, 8:30 pm

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i

  • Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
    Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research1 June 2026, 8:00 pm

    TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program. “Research and clinical evidence continue to be at the core of

  • Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China31 May 2026, 1:06 pm

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea

  • Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
    Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 202630 May 2026, 12:00 pm

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle

  • AHF: Florida Lawmakers Reverse HIV Drug Cuts, Restoring Coverage for Thousands29 May 2026, 6:30 pm

    TALLAHASSEE, Fla.--(BUSINESS WIRE)--Thousands of Floridians living with HIV will keep the medication that keeps them alive, after the Florida Legislature today passed a state budget that reverses this year's cuts to the AIDS Drug Assistance Program (ADAP). The budget returns eligibility to 400 percent of the federal poverty level, brings back the medications the Department of Health had dropped, including Biktarvy, funds the program with $75 million, and adds independent oversight. "This is wha

  • SurGenTec Secures FDA Clearance for ION-C™ - Now Navigation Compatible
    SurGenTec Secures FDA Clearance for ION-C™ - Now Navigation Compatible29 May 2026, 4:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)-- #CervicalSpine--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-C™ navigation instruments for use with the ION-C™ posterior cervical facet fixation implant. The system is engineered for comp

  • Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials
    Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials29 May 2026, 2:14 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Cancer Alliance (TOUCH BBCA), a breast cancer patient advocacy organization, and Navigating Trials, a clinical trial navigation platform serving patients across all cancer types. Through this collaboration, Massive Bio's AI-powered trial matching will be made available directly within both organizations' digital platforms, giving their patient commu

  • Veradermics to Present at Upcoming June Investor Conferences
    Veradermics to Present at Upcoming June Investor Conferences28 May 2026, 8:30 pm

    NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial

  • Stoke Therapeutics to Present at Upcoming Investor Conferences in June
    Stoke Therapeutics to Present at Upcoming Investor Conferences in June28 May 2026, 8:01 pm

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo

  • Tallahassee Memorial HealthCare and Inspirity Health Partners Launch Strategic Supply Chain Partnership
    Tallahassee Memorial HealthCare and Inspirity Health Partners Launch Strategic Supply Chain Partnership28 May 2026, 1:00 pm

    ROCHESTER, Minn.--(BUSINESS WIRE)--Inspirity Health Partners (IHP) has entered into a strategic, multi-year agreement with Tallahassee Memorial HealthCare (TMH) to advance and integrate TMH’s supply chain capabilities through a collaborative, high-performance partnership model. With a well-established category management structure, disciplined operational processes and strong clinical engagement, TMH joins Inspirity from a position of strength. Through this new collaboration, TMH will expand it

  • Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
    Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences28 May 2026, 11:00 am

    CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch

  • Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
    Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 202627 May 2026, 8:05 pm

    HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat

  • Alesis LLC Expands to the Pacific Northwest With Dr. Lyly Fisher — First Seattle-Area Provider of Alesis OSA1™
    Alesis LLC Expands to the Pacific Northwest With Dr. Lyly Fisher — First Seattle-Area Provider of Alesis OSA1™27 May 2026, 6:41 pm

    COCOA BEACH, Fla. & SEATTLE--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA -- a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. Th

  • OpenEvidence Integrates ASCO Guidelines, Figures and Flowcharts into Specialty Oncology Model
    OpenEvidence Integrates ASCO Guidelines, Figures and Flowcharts into Specialty Oncology Model27 May 2026, 4:00 pm

    MIAMI--(BUSINESS WIRE)-- #ASCO--Today, OpenEvidence, the most widely used medical knowledge platform, announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model. As a part of OpenEvidence's commitment to creating advanced AI models for medical specialties, the company has extended their oncology model to include the ASCO Guidelines. ASCO Guidelines will now appear within OpenEvidence answers, accompanied by peer-reviewed evidence, precise citations, and a direct li

  • Groundbreaking Headache Medicine Research on New Frontiers in Treatment, Biomarkers, and the Gut-Brain Axis to be Presented at the American Headache Society® 68th Annual Scientific Meeting
    Groundbreaking Headache Medicine Research on New Frontiers in Treatment, Biomarkers, and the Gut-Brain Axis to be Presented at the American Headache Society® 68th Annual Scientific Meeting27 May 2026, 2:41 pm

    MOUNT ROYAL, N.J.--(BUSINESS WIRE)-- #AHSAM--Leading researchers and clinicians gather June 4–7 for the AHS 68th Annual Scientific Meeting, the premier scientific conference in headache medicine.

  • Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
    Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach27 May 2026, 12:00 pm

    ORLANDO, Fla.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today announced the start of full operations of its newest CenterWell Pharmacy® mail order distribution center, in Orlando, Florida. The $83 million, state-of-the-art facility bolsters capacity for prescription medication delivery across Florida and the country and reinforces Humana’s longstanding commitment to providing members and patients across the Sunshine State with a simp

  • Arima Genomics Announces Presentation of New Data at ASCO 2026 Supporting Clinical Utility of Hi-C Sequencing in Non-Small Cell Lung Cancer
    Arima Genomics Announces Presentation of New Data at ASCO 2026 Supporting Clinical Utility of Hi-C Sequencing in Non-Small Cell Lung Cancer27 May 2026, 12:00 pm

    CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago. The findings in the poster presentation demonstrate the value of Arima’s Hi-C sequencing-based approach to fusion and rearrangement detection, available clinically through t

  • NationsBenefits Selected by Sam’s Club to Lead National Expansion of Modern Hearing Centers
    NationsBenefits Selected by Sam’s Club to Lead National Expansion of Modern Hearing Centers27 May 2026, 11:00 am

    PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare fintech and outcomes platform, today announces its selection by Sam’s Club to manage all Sam’s Club hearing centers across the U.S. This collaboration integrates world-class technology and clinical expertise from NationsHearing® directly into the club to deliver advanced hearing care and outcomes-focused wellness care. These services are designed to improve overall well-being through a modern, member-centric experience

  • Viridian Therapeutics to Participate in Upcoming June Investor Conferences
    Viridian Therapeutics to Participate in Upcoming June Investor Conferences27 May 2026, 11:00 am

    WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare

  • GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
    GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm

    GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.

  • Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm

    HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast o

  • Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 12:00 pm

    WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

  • NeoGenomics to Present New Research at ASCO Annual Meeting 2026
    NeoGenomics to Present New Research at ASCO Annual Meeting 202626 May 2026, 11:05 am

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).

  • Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
    Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting26 May 2026, 11:00 am

    DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r

  • OpenEvidence Launches Voice Mode: The First Native Speech-to-Speech Medical AI
    OpenEvidence Launches Voice Mode: The First Native Speech-to-Speech Medical AI21 May 2026, 4:00 pm

    MIAMI--(BUSINESS WIRE)-- #clinicalai--OpenEvidence, the most widely used medical AI platform among U.S. physicians, today launched Voice Mode, the first native speech-to-speech medical AI interface. With Voice Mode, OpenEvidence becomes the first multimodal medical AI offering a hands-free way for clinicians to ask questions aloud, and hear cited answers read back, on the same peer-reviewed evidence base. The feature is live in the OpenEvidence web and mobile apps and is free for all users. Physicians reach

  • Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities
    Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities21 May 2026, 2:15 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a leader in AI-enabled patient recruitment and oncology solutions, today announced expanded access to oncology clinical trials through AI-powered patient pre-screening leveraging a privacy-preserving clinical data collaboration infrastructure. The initiative enables Massive Bio's artificial intelligence-driven clinical trial matching capabilities to operate securely on sensitive cancer data within BeeKeeperAI’s privacy enhancing platform, EscrowAI

  • Arrivo Bio to Present Clinical Data on Forvisirvat at 2026 ASCP Annual Meeting
    Arrivo Bio to Present Clinical Data on Forvisirvat at 2026 ASCP Annual Meeting21 May 2026, 1:00 pm

    MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy

  • QAD | Redzone Releases New CFO Guide to AI in Manufacturing, Challenging Industry to Focus on Financial Outcomes Over AI Hype
    QAD | Redzone Releases New CFO Guide to AI in Manufacturing, Challenging Industry to Focus on Financial Outcomes Over AI Hype21 May 2026, 12:00 pm

    MIAMI--(BUSINESS WIRE)--QAD | Redzone, the company delivering the leading manufacturing platform, powered by Agentic AI that executes work and decisions across the business, from the shop floor to the top floor, announced the release of A CFO’s Pragmatic Guide to AI in Mid-Market Manufacturing, a new executive white paper designed to help manufacturing leaders navigate the growing wave of AI investment with greater operational and financial discipline. The paper argues that while AI activity ac

  • CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services
    CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services21 May 2026, 12:00 pm

    TAMPA, Fla.--(BUSINESS WIRE)-- #340b--CAN Community Health, the nation’s leading resource in comprehensive health services, today announced a new business entity dedicated to helping health systems, hospitals, physician practices, and specialty clinics unlock the full potential of high-cost specialty therapies while improving patient access, operational efficiency, and long-term sustainability. Healx Solutions launches to support healthcare organizations navigating the growing complexity of specialty m

  • Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
    Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem21 May 2026, 12:00 pm

    BOSTON--(BUSINESS WIRE)--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.

  • Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
    Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference21 May 2026, 11:15 am

    VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av

  • Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
    Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences21 May 2026, 11:00 am

    DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes’ ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych

  • CareDx to Participate in Upcoming Investor Conferences
    CareDx to Participate in Upcoming Investor Conferences20 May 2026, 8:01 pm

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,

  • ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients
    ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients20 May 2026, 8:00 pm

    MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery to power the next wave of mRNA and gene correction therapeutics, today announced the presentation of clinical data from its RCT1100 PCD inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference, held May 15-20, 2026, at the Orange County Convention Center in Orlando, FL. The data represent the first clinical evidence of biological

  • CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors20 May 2026, 12:30 pm

    LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total

  • Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
    Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 202620 May 2026, 12:15 pm

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel

  • Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures20 May 2026, 12:00 pm

    SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F

  • Starfighters Space, Inc. Files First Quarter 2026 Form 10-Q
    Starfighters Space, Inc. Files First Quarter 2026 Form 10-Q20 May 2026, 10:00 am

    CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, is pleased to report its financial results for the first quarter of fiscal 2026 for the period ended March 31, 2026. To review the full financial results, please view the Company’s recent 10-Q filing with the U.S. Securities and Exchange Commission at www.sec.g

  • Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)19 May 2026, 6:15 pm

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data from the first 48 weeks of the ongoing OL treatment period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. IMPALA-2 is the longe

  • Sensome Announces Positive First-in-Human Study Results for In Situ Tumor Detection Technology for Lung Cancer
    Sensome Announces Positive First-in-Human Study Results for In Situ Tumor Detection Technology for Lung Cancer19 May 2026, 1:15 pm

    PARIS--(BUSINESS WIRE)-- #cancer--Sensome announces positive first-in-human results for its in situ tumor detection technology for lung cancer.

  • LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
    LivaNova to Present at Goldman Sachs Global Healthcare Conference in June19 May 2026, 12:00 pm

    LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be

  • CCS Unveils New Research at ISPOR 2026: Longitudinal Coaching and Education Sustain CGM Outcomes Beyond Initiation
    CCS Unveils New Research at ISPOR 2026: Longitudinal Coaching and Education Sustain CGM Outcomes Beyond Initiation19 May 2026, 11:00 am

    ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten

  • Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)18 May 2026, 6:55 pm

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented

  • Visium Powers the Next Generation of Healthy Buildings in America’s Model City
    Visium Powers the Next Generation of Healthy Buildings in America’s Model City18 May 2026, 4:59 pm

    WEST PALM BEACH, Fla.--(BUSINESS WIRE)--As West Palm Beach rapidly emerges as the next model American city, Visium, a leader in Far-UVC environmental control technology, is playing a central role in shaping how modern buildings support health, wellness, and productivity. Headquartered in the heart of CityPlace, Visium is deeply embedded within the transformation led by Related Ross, one of the country’s most influential real estate developers. With over $10 billion committed to Palm Beach Count

  • Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
    Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 202618 May 2026, 3:30 pm

    MORRISVILLE, N.C.--(BUSINESS WIRE)--Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, today announced late-breaking Phase 1 data for its inhaled drug candidate ALX1, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida. The data demonstrates that ALX1, a first-in-class nitric oxide prodrug designed for targeted delivery to the lungs, was well tolerated without safety concerns

  • Entanglement Chief Research Scientist Dr. Fred Glover Ranked #30 Worldwide in Research.com’s 2026 Best Mathematics Scientists List
    Entanglement Chief Research Scientist Dr. Fred Glover Ranked #30 Worldwide in Research.com’s 2026 Best Mathematics Scientists List18 May 2026, 3:00 pm

    MIAMI--(BUSINESS WIRE)-- #ai--Entanglement, Inc., a next-generation computing and AI company advancing quantum logic, optimization, and artificial intelligence, today announced that its Chief Research Scientist, Dr. Fred Glover, has been ranked #30 worldwide and #22 in the United States in Research.com’s 2026 Best Mathematics Scientists ranking. The fifth annual edition of the ranking evaluates more than 3,500 leading researchers across the mathematical sciences using the discipline-specific D-index,

  • Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care
    Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care18 May 2026, 12:00 pm

    LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, today announced the launch of the EB-710US Ultrasound Bronchoscope, a novel next-generation endobronchial ultrasound (EBUS) solution designed to streamline workflow and enhance imaging performance for pulmonologists and healthcare systems. The new scope will be demonstrated at booth #1815 at the American Thoracic Society Conference (ATS), May 18-20 in

  • Ideagen becomes Games first AI Technology Principal Partner and backs Commonwealth Netball
    Ideagen becomes Games first AI Technology Principal Partner and backs Commonwealth Netball18 May 2026, 12:00 pm

    NOTTINGHAM, England--(BUSINESS WIRE)-- #AI--Ideagen, a global software company with its US headquarters in Fort Lauderdale, has been unveiled as the Official AI Technology Principal Partner of Glasgow 2026, Presenting Partner for Netball and an Official Partner for Team Scotland, becoming one of the primary sponsors of the UK’s biggest sporting event this year. Launched in 2009, Ideagen technology sits at the heart of quality, safety and compliance in the world's most regulated and high-compliance in

  • Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences
    Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences15 May 2026, 2:46 pm

    PLANO, Texas--(BUSINESS WIRE)-- #Biotech--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer. Secretome is scheduled to attend the following conferences: Jefferies Global Healthcare Conference June 2 – 4, 2026 New York, New York Oppenheimer CNS & Neuro-Muscular Summi

  • NeoGenomics to Participate in Upcoming Investor Conferences
    NeoGenomics to Participate in Upcoming Investor Conferences15 May 2026, 1:05 pm

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w

  • Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials
    Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials14 May 2026, 2:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global fieldwork and market research provider specializing in healthcare, biotech, life sciences, and pharmaceutical sectors, today announced a strategic partnership focused on connecting cancer patients to clinical trial opportunities through patient communities, advocacy groups, and patient organizations. Under the agreement, Just Worldwide

  • Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain
    Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain14 May 2026, 12:41 am

    ALTAMONTE SPRINGS, Fla.--(BUSINESS WIRE)-- #BiotechInnovation--In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of trea

  • OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing Organization
    OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing Organization13 May 2026, 4:03 pm

    MIAMI--(BUSINESS WIRE)--OrganaBio, LLC ("OrganaBio"), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization. Newly formed OrganaBio subsidiary Excellos Labs, LLC (“Excellos Labs”) will be responsible for San Diego operations going forward. The acquisition creates a mor

  • LaVoie Announces USPTO Renewal of Trademark Registrations for Two Proprietary Communications Methodologies
    LaVoie Announces USPTO Renewal of Trademark Registrations for Two Proprietary Communications Methodologies13 May 2026, 2:12 pm

    BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #DigitalCommunications--LaVoie announces trademark renewal for its LHS Immersion® and The LHS Fifteen-Slide Presentation® communications methodologies

  • Catalyst OrthoScience Appoints Gordon Van Ummersen to Board of Directors
    Catalyst OrthoScience Appoints Gordon Van Ummersen to Board of Directors13 May 2026, 2:00 pm

    NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors. “I am pleased to join Catalyst OrthoScience’s board at this important stage of the company’s evolution,” said Van Ummersen. “Catalyst is an exciting shoulder-focused company that has built a compelling platform focused o

  • Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
    Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing13 May 2026, 12:00 pm

    TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Under the agreement, Catalent will also be granted exclusive manu

  • TherapeuticsMD Announces First Quarter 2026 Financial Results
    TherapeuticsMD Announces First Quarter 2026 Financial Results12 May 2026, 8:05 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations T

  • OutcomeRx Launches Innovative Targeted Stop-Loss Insurance Product Covering CAR T-Cell and Gene Therapies
    OutcomeRx Launches Innovative Targeted Stop-Loss Insurance Product Covering CAR T-Cell and Gene Therapies12 May 2026, 5:13 pm

    ORLANDO, Fla.--(BUSINESS WIRE)--OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss, a stand-alone medical stop-loss insurance product that reimburses covered expenses on qualified claims for Gene and CAR T-cell therapies for group health plans and their coordinating Stop-Loss carrier. This innovative solution, in addition to reimbursement for certain FDA approved Prescription Drugs, uniquely reimburses administration of the Prescription Drug and t

  • PriceMDs Launches Industry-First API Integration Platform to Simplify Specialty Medication Sourcing and Tracking
    PriceMDs Launches Industry-First API Integration Platform to Simplify Specialty Medication Sourcing and Tracking12 May 2026, 2:07 pm

    CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs today announced the launch of a new API integration platform designed to help pharmacy benefit managers (PBMs), third-party administrators (TPAs), and healthcare organizations streamline prescription sourcing and specialty medication management within their existing workflows. The platform connects pricing, patient onboarding, regulatory documentation, shipment tracking, and claims reporting into a single integration, reducing the need for manual proc

  • HSS Research Supports Routine Imaging Before and After ACL Surgery in Growing Children
    HSS Research Supports Routine Imaging Before and After ACL Surgery in Growing Children12 May 2026, 1:36 pm

    ORLANDO, Fla.--(BUSINESS WIRE)--At this year’s Pediatric Orthopedic Society of North America (POSNA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies evaluating outcomes for three of the most common anterior cruciate ligament (ACL) reconstruction techniques designed to protect open growth plates in young patients who are still growing. The findings highlight the importance of using imaging before and after surgery to accurately identify and monitor alignme

  • Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
    Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference11 May 2026, 8:05 pm

    SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20

  • Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 202611 May 2026, 8:01 pm

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or

  • Alesis LLC Announces First Sleep Center Partnership for Alesis OSA1™ Treatment of the Root Cause of Most Sleep Apnea
    Alesis LLC Announces First Sleep Center Partnership for Alesis OSA1™ Treatment of the Root Cause of Most Sleep Apnea11 May 2026, 5:08 pm

    COCOA BEACH, Fla. & MOORESVILLE, N.C.--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device and headquartered on Florida’s Space Coast in Cocoa Beach, today announced a joint venture partnership with Lake Norman Pulmonary & Sleep in Mooresville, North Carolina — making it the first sleep medicine practice in the Piedmont region to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP

  • OpenEvidence and Society of Surgical Oncology Announce Strategic Partnership to Advance Surgical Cancer Care and Launch SSO Innovator Grant
    OpenEvidence and Society of Surgical Oncology Announce Strategic Partnership to Advance Surgical Cancer Care and Launch SSO Innovator Grant11 May 2026, 4:00 pm

    MIAMI & ROSEMONT, Ill.--(BUSINESS WIRE)-- #MedicalAI--Today, the Society of Surgical Oncology (SSO), a global professional society for cancer surgeons, and OpenEvidence, the most widely used medical knowledge platform, announced a strategic partnership to strengthen access to the most trusted surgical oncology evidence at the point of care while building a foundation for innovative collaborations to support surgeons and all physicians taking care of patients with cancer. Together, SSO and OpenEvidence will

  • LTM Introduces SAP Centric AI Powered Platform to Orchestrate Intelligent, Autonomous Enterprise Operations
    LTM Introduces SAP Centric AI Powered Platform to Orchestrate Intelligent, Autonomous Enterprise Operations11 May 2026, 1:45 pm

    MUMBAI, India & ORLANDO, Fla.--(BUSINESS WIRE)---- $LTM #AI--LTM today announced the launch of the LTM Business Orchestration platform to orchestrate intelligent and autonomous enterprise operations across SAP.

  • United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 202611 May 2026, 10:30 am

    SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve

  • Coolibar and Skin Cancer Survivor and Advocate, Dayanara Torres, Redefine Life in the Sun for Skin Cancer Awareness Month
    Coolibar and Skin Cancer Survivor and Advocate, Dayanara Torres, Redefine Life in the Sun for Skin Cancer Awareness Month8 May 2026, 8:31 pm

    MIAMI--(BUSINESS WIRE)-- #Coolibar--Coolibar, the world’s leading UPF 50+ sun protection apparel brand, is continuing its partnership with skin cancer survivor and advocate Dayanara Torres and the Melanoma Research Foundation (MRF) for Skin Cancer Awareness Month this May. The 2026 campaign brings a more intimate and elevated creative direction to Coolibar’s sun safety message, using emotional storytelling to encourage prevention, protection, and early detection. Together, the partners aim to reach communi

  • Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
    Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American8 May 2026, 8:00 pm

    OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co

  • Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
    Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology8 May 2026, 3:18 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced that SkinCure Oncology and Sensus Healthcare have amicably resolved their dispute and are moving forward constructively with a shared commitment to patient care and clinical excellence. In March 2026, Sensus Healthcare filed a lawsuit in the Circuit Court for the Fifteenth Judicial Cir

  • Bruno Vision Care Wins 2026 MedTech Breakthrough Award
    Bruno Vision Care Wins 2026 MedTech Breakthrough Award8 May 2026, 2:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)-- #ContactLenses--Bruno Vision Care's FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award.

  • Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
    Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights7 May 2026, 8:05 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. Excluding sales to the Company’s historically largest customer, rev

  • Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
    Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights7 May 2026, 8:05 pm

    PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for

  • Catalyst Fracture System Wins Medical Device Engineering Breakthrough Designation in 2026 MedTech Breakthrough Awards Program
    Catalyst Fracture System Wins Medical Device Engineering Breakthrough Designation in 2026 MedTech Breakthrough Awards Program7 May 2026, 2:00 pm

    NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that the Catalyst Fracture System received the “Medical Device Engineering Breakthrough” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies

  • Alnylam to Webcast Presentations at Upcoming Investor Conferences
    Alnylam to Webcast Presentations at Upcoming Investor Conferences7 May 2026, 12:00 pm

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be

  • Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
    Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences6 May 2026, 1:00 pm

    CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Gilead's Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF5 May 2026, 6:40 pm

    LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida’s and other States’ AIDS Drug Programs Falters, says AHF

  • The Global Initiative for Asthma and OpenEvidence Partner to Deliver Asthma Strategy to Physicians Worldwide
    The Global Initiative for Asthma and OpenEvidence Partner to Deliver Asthma Strategy to Physicians Worldwide5 May 2026, 4:00 pm

    FONTANA, Wis. & MIAMI--(BUSINESS WIRE)-- #Asthma--The Global Initiative for Asthma (GINA) collaborates with OpenEvidence to make GINA’s evidence-based asthma strategy reports, clinical recommendations, and educational resources available directly through OpenEvidence. Under the agreement, OpenEvidence becomes a key content partner for GINA, driving the digital dissemination of asthma standards to clinicians across OpenEvidence’s rapidly expanding international footprint. Asthma affects more than 300 mill

  • Call 4 Health Awarded Call Center Services Agreement With Premier, Inc.
    Call 4 Health Awarded Call Center Services Agreement With Premier, Inc.5 May 2026, 3:58 pm

    DELRAY BEACH, Fla.--(BUSINESS WIRE)--Call 4 Health has been awarded a national group purchasing agreement for Call Center Services with Premier, Inc. Effective February 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Medical Answering, Appointment Scheduling, Telephone Nurse Triage, and Clinical Trial Recruitment and Retention services. “Being selected by Premier is a meaningful milestone for Ca

  • Precision IO Group Launches U.S. Clinical Study of Epione® Robotic System for the Treatment of Bone Lesions
    Precision IO Group Launches U.S. Clinical Study of Epione® Robotic System for the Treatment of Bone Lesions5 May 2026, 1:34 pm

    MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of Quantum Surgical, announced the launch of EPIOS, a new U.S. clinical study evaluating the safety and performance of the Epione® robotic platform for the treatment of bone tumors and metastases. The study is designed to support the expansion of Epione’s market approvals in the United States. The first patient was treated on April 28, 2026, in a leading cancer center based in Miami, Florida. Epione has been CE marked for bone indic

  • South Florida Community Rallies to Raise a Record $1.7 Million at FedEx/St. Jude Angels and Stars Gala
    South Florida Community Rallies to Raise a Record $1.7 Million at FedEx/St. Jude Angels and Stars Gala5 May 2026, 12:00 pm

    MIAMI--(BUSINESS WIRE)--The FedEx/St. Jude Angels and Stars Gala united the Miami and South Florida community, raising a record $1.7 million for St. Jude Research Hospital.

  • Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
    Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress5 May 2026, 11:01 am

    WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline data fro

  • OpenEvidence and ACOG Announce Strategic Collaboration to Advance Ob-Gyn Health Care
    OpenEvidence and ACOG Announce Strategic Collaboration to Advance Ob-Gyn Health Care4 May 2026, 4:00 pm

    MIAMI & WASHINGTON--(BUSINESS WIRE)--Today, OpenEvidence and American College of Obstetricians & Gynecologists (ACOG) announced a strategic collaboration to expand access to ACOG’s evidence-based clinical guidance and develop insights to help inform the future of ob-gyn care and women’s health. The collaboration brings together ACOG, the leading professional membership organization and author of clinical guidance for obstetrician–gynecologists, and OpenEvidence, the most widely used medical

  • Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
    Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 20264 May 2026, 11:00 am

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Fl

  • Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems
    Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems1 May 2026, 6:00 pm

    FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., a global leader in diabetes management, today provided an important update to the medical device labeling correction it announced on February 6, 2026, for all TRUE METRIX®, TRUE METRIX® AIR, TRUE METRIX® GO, and TRUE METRIX® PRO Blood Glucose Monitoring Systems (collectively, the “Products”). Since the February 6, 2026 communication, Trividia Health has been actively updating the labeling and providing messaging to ensure that users

  • Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
    Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program1 May 2026, 12:00 pm

    INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider Recognition Program. The program spotlights the top one percent of primary care providers in Elevance Health’s nationwide affiliated health plan network of about 7,200 value-based care and evaluated provider partners. The recognition highlights primary care providers who exhibit excellence in deliv

  • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 202630 April 2026, 8:32 pm

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects ass

  • Align Technology Showcases Latest Advances in Integrated Digital Orthodontics and Previews 2026 Innovation at AAO Annual Session
    Align Technology Showcases Latest Advances in Integrated Digital Orthodontics and Previews 2026 Innovation at AAO Annual Session30 April 2026, 6:55 pm

    ORLANDO, Fla. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared a preview of what orthodontists and their teams can expect from the Company (booth #1643) during the American Association of Orthodontists (AAO) 2026 Annual Session, taking

  • CONMED Corporation Announces First Quarter 2026 Financial Results
    CONMED Corporation Announces First Quarter 2026 Financial Results29 April 2026, 8:05 pm

    LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from th

  • Tandem Diabetes Care Announces Upcoming Conference Presentations
    Tandem Diabetes Care Announces Upcoming Conference Presentations29 April 2026, 8:05 pm

    SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 5:20 pm Eastern Time (2:20 pm Pacific Time), and Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 3:20 pm Eastern Time (12:20 pm Pacific Time). The presentations

  • ReliaQuest and Florida State University Launch AI and Cybersecurity Partnership to Accelerate Research and Real-World Innovation
    ReliaQuest and Florida State University Launch AI and Cybersecurity Partnership to Accelerate Research and Real-World Innovation29 April 2026, 2:00 pm

    TALLAHASSEE, Fla. & TAMPA, Fla.--(BUSINESS WIRE)--ReliaQuest and Florida State University (FSU) today announced a new partnership designed to advance research and real-world application of artificial intelligence in cybersecurity. Made possible by a $1.5 million philanthropic investment from ReliaQuest, the collaboration will establish the annual ReliaQuest Innovation Challenge at FSU to incentivize faculty research into some of the most complex use-cases for this dynamic field. The partnership

  • NeoGenomics Reports First Quarter 2026 Results
    NeoGenomics Reports First Quarter 2026 Results28 April 2026, 8:05 pm

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.

  • Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
    Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks28 April 2026, 8:00 pm

    OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through Ap

  • Draig Therapeutics to Present at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting
    Draig Therapeutics to Present at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting28 April 2026, 3:00 pm

    NEWTON, Mass.--(BUSINESS WIRE)--Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies, announced today that the company will present an oral presentation and two posters at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting. Oral presentation details are below: DT-101 – a Novel alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Receptor (AMPAR) Positive Allosteric Modulator Demonstrates Favorable Tolera

  • AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities27 April 2026, 10:15 pm

    LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

  • Eight Student Teams Named National Winners of 34th Annual ExploraVision Competition
    Eight Student Teams Named National Winners of 34th Annual ExploraVision Competition27 April 2026, 8:32 pm

    MCLEAN, Va.--(BUSINESS WIRE)-- #ExploraVision--Toshiba and the National Science Teaching Association (NSTA) today announce eight national winners of the 34th annual Toshiba/NSTA ExploraVision competition, the world’s largest K-12 science competition. This year’s winners have shared innovative proposals to help overcome some of the greatest challenges facing the world today, from healthcare challenges to transportation efforts to protecting the environment. The Toshiba/NSTA ExploraVision competition is designed

  • OpenEvidence Collaborates With NCCN to Integrate Canonical Oncology Treatment Algorithms at the Point-of-Care
    OpenEvidence Collaborates With NCCN to Integrate Canonical Oncology Treatment Algorithms at the Point-of-Care27 April 2026, 4:00 pm

    MIAMI--(BUSINESS WIRE)-- #MedicalAI--OpenEvidence now integrates National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) directly in answers, grounding responses in the pinnacle reference resource defining and advancing care in oncology. OpenEvidence’s collaboration with NCCN marks the beginning of a series of focused oncology-related updates to the platform—in conjunction with leading experts in oncology—to help clinicians give the best possible care to pa

  • Availity’s Inaugural Abrasion Index Reveals Where Payer-Provider Friction Hits Healthcare Hardest
    Availity’s Inaugural Abrasion Index Reveals Where Payer-Provider Friction Hits Healthcare Hardest27 April 2026, 1:05 pm

    JACKSONVILLE, Fla.--(BUSINESS WIRE)--Availity releases its first annual Abrasion Index, measuring friction between health plans and providers.

  • American Ocean Minerals Announces Anuanua Moana Active Deployment to Advance Deep-Sea Research and Environmental Research Campaigns
    American Ocean Minerals Announces Anuanua Moana Active Deployment to Advance Deep-Sea Research and Environmental Research Campaigns27 April 2026, 12:30 pm

    TAMPA, Fla.--(BUSINESS WIRE)--Today, American Ocean Minerals Corporation (AOMC) announced deployment on the next phase of scientific research activities of the MV Anuanua Moana, a proprietary research vessel advancing critical deep-sea environmental and exploration programs across its operating areas. The deployment reflects a key operational capability underpinning AOMC’s recently announced definitive merger agreement with Odyssey Marine Exploration (NASDAQ: OMEX), which will create a premier,

  • IonQ and Florida LambdaRail Launch First Statewide Quantum-Safe Network Initiative in United States
    IonQ and Florida LambdaRail Launch First Statewide Quantum-Safe Network Initiative in United States27 April 2026, 12:00 pm

    MIAMI--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading quantum platform company, and Florida LambdaRail (FLR), Florida’s existing statewide research and education fiber optic network, announced an agreement to support delivering on FLR's vision for a quantum-safe network spanning Florida. Together with Florida Quantum and local colleges and universities, the groups’ first step will seek to create a nearly 100 mile quantum corridor from Palm Beach County to Miami-Dade connecting three re

  • Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 202623 April 2026, 9:56 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions. Participants are encour

  • MITER Foundation Celebrates National Volunteer Week With Continued Commitment to Community Impact
    MITER Foundation Celebrates National Volunteer Week With Continued Commitment to Community Impact23 April 2026, 5:31 pm

    HARRISBURG, Pa.--(BUSINESS WIRE)--MITER Foundation, the charitable arm of MITER Brands, a family of leading window and door brands, is celebrating National Volunteer Week, taking place on April 19 - 25, 2026, with expanded volunteer efforts to solidify its continued commitment to community impact. In honor of National Volunteer Week, the manufacturer is participating, volunteering, and sponsoring several events across its family of brands, including an Adopt-A-Highway Roadside Cleanup in Harris

  • NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
    NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration23 April 2026, 11:05 am

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.

  • AHF Webinar Spotlights Equity as Pandemic Agreement Nears Finish Line
    AHF Webinar Spotlights Equity as Pandemic Agreement Nears Finish Line22 April 2026, 9:33 pm

    MIAMI--(BUSINESS WIRE)-- #COVID--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Will Equity Prevail? The PABS Annex Negotiations at Their Final Hour,” on Thursday, April 23, 2026 at 10:00 AM EDT, virtually via Zoom. Register here. As WHO Pandemic Agreement negotiations enter a decisive phase ahead of the next Intergovernmental Working Group (IGWG) session, Member States are working to finalize the Pathogen Access and Bene

  • As Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical Development
    As Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical Development22 April 2026, 2:26 pm

    MIAMI--(BUSINESS WIRE)-- #Biotech--The recent federal action directing the FDA to accelerate the review of psychedelic therapies marks a major shift in the development of next-generation mental health treatments. With regulatory timelines compressing and new federal support behind this category, compounds such as psilocybin and ibogaine are moving closer to broader clinical use. For a field that remained largely dormant for decades, this moment represents a clear turning point. “This is an inflection poin

  • DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
    DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)22 April 2026, 1:45 pm

    MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for DMX-1001 (oral noribogaine), a novel neuroplastogen therapeutic for the treatment of alcohol use disorder (AUD). The company recently completed a multiple ascending dose (MAD) clinical trial of DMX-1001 in healthy volunteers. Results from

  • OrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug Product
    OrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug Product22 April 2026, 1:05 pm

    MIAMI & SANTA FE, Calif.--(BUSINESS WIRE)-- #biotech--OrganaBio and RxMP Therapeutics announced a manufacturing partnership for the cGMP production of RMP-402, a first-in-class hemostatic therapeutic.

  • TimeDoc Health Boosts Patient Engagement by 76% and Drives $33k in Combined Monthly Revenue Growth for Partner Practices via SmartTouch® Engage
    TimeDoc Health Boosts Patient Engagement by 76% and Drives $33k in Combined Monthly Revenue Growth for Partner Practices via SmartTouch® Engage22 April 2026, 1:00 pm

    TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leading provider of cellular-enabled remote patient monitoring (RPM) solutions, today announced breakthrough results from its collaboration with TimeDoc Health, showcasing the powerful impact of its SmartTouch® Engage program—an omni-channel, human-to-human, AI-enhanced patient engagement and device utilization solution that helps improve clinical and financial outcomes, while removing administrative burden for healthcare organizations. Following t

  • Nicklaus Children's Hospital is First in Region to Offer Sedation-Free Evaluation of Upper Gastrointestinal Tract in Children
    Nicklaus Children's Hospital is First in Region to Offer Sedation-Free Evaluation of Upper Gastrointestinal Tract in Children22 April 2026, 11:04 am

    DENVER--(BUSINESS WIRE)-- #FEEES--EvoEndo®, Inc. (EvoEndo) announces that Nicklaus Children’s Hospital is the first in South Florida to offer sedation-free transnasal endoscopy (TNE) using the EvoEndo System to evaluate the upper digestive tract in children. TNE can be used as an alternative to traditional upper endoscopy performed through the mouth for patients and their families who prefer to avoid sedation and the associated inconveniences. A sedation-free alternative is more convenient for patients

  • Thiel Foundation Announces 2026 Class of Thiel Fellows
    Thiel Foundation Announces 2026 Class of Thiel Fellows21 April 2026, 3:00 pm

    MIAMI--(BUSINESS WIRE)--Today, The Thiel Foundation has officially unveiled its 2026 class of Thiel Fellows, rewarding an ambitious and bright class of young people ready to disrupt and redesign industries across the United States and the world. Established in 2011, the two-year Thiel Fellowship awards grants to extraordinary young entrepreneurs, affording them the opportunity to untether themselves from groupthink and traditional tracks. Each fellow in this year’s class will receive an award o

  • AHF Launches Statewide Campaign Urging Full Restoration of Florida's AIDS Drug Assistance Program21 April 2026, 2:35 pm

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Launches Statewide Campaign Urging Full Restoration of Florida's AIDS Drug Assistance Program

  • Clinical Trial Shows that Treatment with Kerecis Intact Fish-Skin Grafts Shortens Hospital Stays for Severely Burned Patients
    Clinical Trial Shows that Treatment with Kerecis Intact Fish-Skin Grafts Shortens Hospital Stays for Severely Burned Patients16 April 2026, 2:03 pm

    ORLANDO, Fla.--(BUSINESS WIRE)-- #kerecis--Study shows Kerecis fish-skin grafts reduce hospital stays for burn patients by 9.3 days compared to synthetic grafts, with lower complication rates.

  • Catalyst OrthoScience Demonstrates Leadership in Procedural Efficiency with Addition of Fracture to Its Single-Tray Portfolio
    Catalyst OrthoScience Demonstrates Leadership in Procedural Efficiency with Addition of Fracture to Its Single-Tray Portfolio16 April 2026, 2:00 pm

    NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the expansion of its single-tray portfolio, with the introduction of a single tray option for the Catalyst Fracture system, at the upcoming Shoulder360™ Annual Meeting. This milestone represents a significant advancement in shoulder surgery workflow efficiency and gives surgeons partne

  • Starfighters Space, Inc. files Fiscal 2025 Annual Report
    Starfighters Space, Inc. files Fiscal 2025 Annual Report16 April 2026, 12:50 am

    CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world’s largest fleet of commercial supersonic aircraft, is pleased to report, in accordance with NYSE American requirements, the filing of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). This Form 10-K filing, which in

  • SurGenTec Secures FDA 510(k) Clearance for TiLink™ SI joint fusion- Now Navigation Compatible
    SurGenTec Secures FDA 510(k) Clearance for TiLink™ SI joint fusion- Now Navigation Compatible15 April 2026, 4:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)---- $ISRG #FDAcleared--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its TiLink™ Navigation Instruments for use with the TiLink™ SI Joint Fusion System in sacroiliac joint procedures. The system is engineered for compatibility with Medtronic’s StealthStation™ navigation platform, enabling enhanced precision during minimally invasive SI joint fusion surgeries.

  • Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution
    Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution15 April 2026, 1:51 pm

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #amlodipine--Sdamlo, by Pangea Pharmaceuticals, is an FDA-approved amlodipine, unit-dose, alcohol-free solution for pediatric, geriatric, and tube-fed patients.

  • Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results14 April 2026, 9:00 pm

    OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i

  • Orlando Community Unites at 2026 Susan G. Komen® MORE THAN PINK Walk
    Orlando Community Unites at 2026 Susan G. Komen® MORE THAN PINK Walk14 April 2026, 3:37 pm

    ORLANDO--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, will bring together breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the Central Florida MORE THAN PINK Walk on Saturday, May 9, 2026. The Orlando community will come together to make sure no one faces breast cancer alone and help advance Komen’s mission to save lives through research, public policy, education and care. This year, Komen aims to raise $210,000 at

  • LifeStream Behavioral Center and Greenspace Health Partner to Advance Data-Informed Behavioral Healthcare Across Central Florida
    LifeStream Behavioral Center and Greenspace Health Partner to Advance Data-Informed Behavioral Healthcare Across Central Florida14 April 2026, 1:03 pm

    TORONTO & LEESBURG, Fla.--(BUSINESS WIRE)-- #CARF--Greenspace Health and LifeStream Behavioral Center, a leading nonprofit provider of behavioral health and social services in Central Florida, have partnered to implement Measurement-Based Care (MBC) across LifeStream’s full continuum of programs. The collaboration will leverage data-driven insights and patient-reported outcome measures (PROMs) within the care process to improve service quality and clinical outcomes for thousands of individuals served a

  • Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
    Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference14 April 2026, 12:05 pm

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS International Conference in Orlando, Florida, May 17-20, 2026. Oral Presentation Title: Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Mini Sympo

  • Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing14 April 2026, 1:57 am

    SAN FRANCISCO--(BUSINESS WIRE)-- #AHFcares--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

  • NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
    NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 202613 April 2026, 11:05 am

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.

  • Prodalim Expands Solos Technology Platform in the United States with New California Operations
    Prodalim Expands Solos Technology Platform in the United States with New California Operations13 April 2026, 10:24 am

    WINTER GARDEN, Fla.--(BUSINESS WIRE)--Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its Solos platform in the United States with the launch of operations at a new facility in Hopland, California. The new site marks a key milestone in the continued globalization of Solos, Prodalim’s patented aroma recovery and beverage innovation platform, and positions Solos at the center of one of the world’s most important wine-producing regions, stre

  • Ayco Farms Clarifies FDA Enforcement Report Listing: No Active Recall and No Product in Market
    Ayco Farms Clarifies FDA Enforcement Report Listing: No Active Recall and No Product in Market10 April 2026, 10:33 pm

    POMPANO BEACH, Fla.--(BUSINESS WIRE)--Ayco Farms, Inc. (“Ayco Farms”) today issued a clarification regarding recent media coverage tied to its inclusion in the U.S. Food and Drug Administration’s weekly Enforcement Report. The listing reflects a previously completed, voluntary recall of fresh whole cantaloupes that were distributed between December 12, 2025, and January 16, 2026, due to “potential” Salmonella contamination. There is no active recall, and no product subject to this notice is cur

  • AHF Slams Gilead for Role in Florida AIDS Drug Crisis
    AHF Slams Gilead for Role in Florida AIDS Drug Crisis10 April 2026, 5:01 pm

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis

  • Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
    Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision10 April 2026, 12:00 pm

    JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision

  • Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients
    Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients9 April 2026, 2:17 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced the publication of a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology demonstrating that its neuro-symbolic, multi-agent artificial intelligence platform can match cancer patients to clinical trials four times faster than conventional methods, with measurable accuracy, transparency, and equity, in routine clinical practice. The study, "Transforming oncology clinical t

  • Cartherics and Catalent Expand Commercial License Agreement
    Cartherics and Catalent Expand Commercial License Agreement9 April 2026, 12:00 pm

    MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p

  • American Ocean Minerals Corporation to Merge with Odyssey Marine Exploration, Inc., Creating a $1B U.S.-Controlled Deep-Sea Critical Minerals Platform
    American Ocean Minerals Corporation to Merge with Odyssey Marine Exploration, Inc., Creating a $1B U.S.-Controlled Deep-Sea Critical Minerals Platform8 April 2026, 11:30 am

    TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation (“AOMC”) and Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) (“Odyssey”) today announced they have entered into a definitive merger agreement to combine their businesses and create a leading deep-sea critical minerals research and resource extraction platform (the “Transaction”). The Transaction values the combined company at approximately $1 billion and includes a private placement of over $150 million from prominent institution

  • CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets
    CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets7 April 2026, 5:13 pm

    MIAMI--(BUSINESS WIRE)-- #catsofinstagram--Petwealth raises $1.7M, advancing at-home pet PCR diagnostics, AI health insights, and key partnerships in vet telehealth and pet service software.

  • Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
    Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare7 April 2026, 1:00 pm

    MIAMI--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, and medical aesthetics practices that integrate ALASTIN’s comprehensive regenerative skincare portfolio into treatment planning and patient care. Colorado Springs Dermatology Clinic is the first ALASTIN Signature Practice, with additional Signature Practices planned across the United States in 2026

  • PaceMate Appoints Cardiac Electrophysiologist and NIH-Funded Researcher Benjamin A. Steinberg, MD, MHS, FACP, FACC, FHRS as Chief Medical Officer7 April 2026, 12:00 pm

    TAMPA, Fla.--(BUSINESS WIRE)--PaceMate, a tech-enabled cardiac device monitoring platform managing care for more than 2.3 million patients at health systems nationwide, announced the appointment of Dr. Benjamin A. Steinberg as Chief Medical Officer. A nationally recognized leader in cardiac electrophysiology, NIH-funded researcher, and author of nearly 200 peer-reviewed publications, Dr. Steinberg brings to PaceMate a rare combination of clinical depth, research rigor, and real-world expertise

  • NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
    NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 20267 April 2026, 11:05 am

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls

  • FDA Grants De Novo Classification to neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes
    FDA Grants De Novo Classification to neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes7 April 2026, 11:00 am

    GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusion MRI data t

  • Allevion Medical™ Receives 510K Clearance for Vantage™ — A Fully Disposable Kit Featuring a Novel Approach to Spinal Decompression
    Allevion Medical™ Receives 510K Clearance for Vantage™ — A Fully Disposable Kit Featuring a Novel Approach to Spinal Decompression3 April 2026, 3:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)-- #AllevionMedical--Allevion Medical today announced the FDA clearance of Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally invasive lumbar decompression procedures. Developed to address pain associated with hypertrophic bone growth, Vantage™ enables targeted decompression through a patented approach that combines precision with procedural control. The system follows an intuitive, reproducible workflow—locate, dilate, decompress—that helps ph

  • CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 20262 April 2026, 8:05 pm

    LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro

  • Partnership between Tasso and the Parkinson’s Foundation Reveals New Genetic Data
    Partnership between Tasso and the Parkinson’s Foundation Reveals New Genetic Data31 March 2026, 12:00 pm

    NEW YORK & MIAMI & SEATTLE--(BUSINESS WIRE)-- #ParkinsonsAwarenessMonth--PD GENEration collaboration broadens participation in Parkinson’s genetic research through flexible, patient-centered blood collection.

  • TherapeuticsMD Announces Full Year 2025 Financial Results
    TherapeuticsMD Announces Full Year 2025 Financial Results30 March 2026, 8:05 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

  • Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company
    Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company30 March 2026, 2:00 pm

    TAMPA, Fla.--(BUSINESS WIRE)-- #ashatherapeutics--Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company using AI-enabled molecular design technology

  • Kain Capital Completes Investment in White Wilson Medical Center and Appoints Brad Logan as CEO
    Kain Capital Completes Investment in White Wilson Medical Center and Appoints Brad Logan as CEO30 March 2026, 12:00 pm

    NEW YORK & FORT WALTON BEACH, Fla.--(BUSINESS WIRE)--Kain Capital LLC ("Kain") today announced the completion of its investment in White Wilson Medical Center, P.A. ("White Wilson"), the Emerald Coast’s largest independent multi-specialty physician group. Concurrent with the investment, Brad Logan has been appointed Chief Executive Officer. Founded in 1946, White Wilson has grown into the region’s leading independent physician group, operating nine clinic locations across Fort Walton Beach, Cre

  • United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-230 March 2026, 11:00 am

    SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the change in absolute forced vital capacity (FVC) by 130.1 mL (Hodges-Lehmann [H-L] estimate, 95% confidence interval [CI], 82.2 to 178.1 m

  • Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
    Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 202627 March 2026, 12:15 pm

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and

  • Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract27 March 2026, 12:00 pm

    BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus pr

  • StarLIMS to Acquire the MODA® Platform from Lonza, Expanding Deeper Into Manufacturing Operations & Quality Control
    StarLIMS to Acquire the MODA® Platform from Lonza, Expanding Deeper Into Manufacturing Operations & Quality Control25 March 2026, 1:00 pm

    HOLLYWOOD, Fla.--(BUSINESS WIRE)--StarLIMS has agreed to acquire the MODA® Platform, a trusted solution for manufacturing quality assurance and control in regulated environments. The transaction is expected to close in Q2 2026, subject to customary closing conditions. StarLIMS is a leading provider of enterprise laboratory informatics software. The acquisition of the MODA® Platform from Lonza, one of the world’s largest contract development and manufacturing organizations, will enable StarLIMS

  • Governor Signs Emergency Legislation Restoring HIV Medication Access for More Than 12,000 Floridians
    Governor Signs Emergency Legislation Restoring HIV Medication Access for More Than 12,000 Floridians24 March 2026, 7:46 pm

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Governor Ron DeSantis has signed into law emergency legislation restoring access to life-saving HIV medications for more than 12,000 Floridians who lost coverage when the Florida Department of Health cut the state’s AIDS Drug Assistance Program on March 1. The legislation, which passed both chambers of the Florida Legislature unanimously, appropriates $30.9 million in emergency bridge funding through June 30, 2026, restores Florida’s AIDS Drug Assistance

  • X-lumin Achieves Roundtrip Optical Transmission to LEO Satellite Using 15cm Portable Terminal
    X-lumin Achieves Roundtrip Optical Transmission to LEO Satellite Using 15cm Portable Terminal24 March 2026, 6:07 pm

    MERRITT ISLAND, Fla.--(BUSINESS WIRE)-- #FreeSpaceOptics--X-lumin has successfully demonstrated a roundtrip optical transmission from its 15cm Optical Ground Terminal (OGT) to a retroreflector-equipped LEO satellite, and back, with the ability to track downlink signals that are 106 times dimmer than the current standard of 25µW/m2. The demonstration was repeated over multiple passes during recent testing, marking the first time a portable, low SWaP (Size, Weight, Power) terminal has closed a roundtrip optical lin

  • Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
    Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue20 March 2026, 8:17 pm

    ORLANDO, Fla.--(BUSINESS WIRE)-- #Alzheimers--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential

  • Dentalcorp Launches First Annual Dental Technology Demo Day Offering US$100,000 Investment and Potential Pilot Opportunity
    Dentalcorp Launches First Annual Dental Technology Demo Day Offering US$100,000 Investment and Potential Pilot Opportunity19 March 2026, 12:00 pm

    ORLANDO, Fla.--(BUSINESS WIRE)-- #DSO--Dentalcorp, one of North America's largest dental support organizations, today announced its inaugural Demo Day, a live dental technology competition taking place June 24 at the Gaylord Palms Resort & Convention Center in Orlando, Florida. The event will award a US$100,000 SAFE investment and a potential pilot opportunity to the winning company, with access to a network of more than 600 practices serving 5.7 million patients annually. Applications are open no

  • LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites
    LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites19 March 2026, 11:30 am

    BOCA RATON, Fla.--(BUSINESS WIRE)-- #505b2--LGM Pharma’s additional investments in its Texas and Colorado sites will support growing demand for U.S.-based end-to-end pharma manufacturing.

  • Real Time Medical Systems to Present Data-Driven Strategies for Reducing Readmissions at AAPACN 2026
    Real Time Medical Systems to Present Data-Driven Strategies for Reducing Readmissions at AAPACN 202617 March 2026, 12:00 pm

    BALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its participation in the American Association for Post-Acute Care Nursing (AAPACN) 2026 Conference, taking place March 17–20 in Orlando, FL. As nursing professionals convene to explore best practices and emerging clinical innovations, Real Time and North Shore Health will highlight how live, data-driven approaches help post-acu

  • Redwire Elects The Honorable Frank Calvelli to Board of Directors
    Redwire Elects The Honorable Frank Calvelli to Board of Directors17 March 2026, 11:30 am

    JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, today announced that its Board of Directors has elected The Honorable Frank Calvelli as its newest member, effective March 12, 2026. Calvelli previously served as Assistant Secretary of the Air Force for Space Acquisition and Integration and was the Pentagon’s first service acquisition executive for U.S. Space Force space systems and programs. In this role, Calvel

  • Renowned Radiosurgery Provider Fully Transitions to ZAP-X® Gyroscopic Radiosurgery® Platform, Marking New Era of Advanced Cranial Radiosurgery
    Renowned Radiosurgery Provider Fully Transitions to ZAP-X® Gyroscopic Radiosurgery® Platform, Marking New Era of Advanced Cranial Radiosurgery17 March 2026, 11:15 am

    SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that the Miami Neuroscience Center at Larkin Community Hospital has fully transitioned its stereotactic radiosurgery (SRS) program from earlier-generation cobalt-60 (Co-60)–based technology to the modern ZAP-X® Gyroscopic Radiosurgery® platform. Since December 2025, all cranial radiosurgery procedures at the center are now performed using the next-generation ZA

  • OpenEvidence and AAO-HNSF Pioneer a New Model for Updating Clinical Practice Guidelines
    OpenEvidence and AAO-HNSF Pioneer a New Model for Updating Clinical Practice Guidelines16 March 2026, 1:00 pm

    ALEXANDRIA, Va. & MIAMI--(BUSINESS WIRE)--AAO-HNSF and OpenEvidence use AI to update clinical practice guidelines and align standards of care with the latest clinical evidence as it evolves.

  • NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
    NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling16 March 2026, 11:05 am

    FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program.

  • Cryo-Cell Receives NYSE American Continued Listing Notice
    Cryo-Cell Receives NYSE American Continued Listing Notice12 March 2026, 9:00 pm

    OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com

  • National Organization for Rare Disorders and OpenEvidence Partner to Bring AI-Powered Rare Disease Resources to Clinicians and Patients Worldwide
    National Organization for Rare Disorders and OpenEvidence Partner to Bring AI-Powered Rare Disease Resources to Clinicians and Patients Worldwide12 March 2026, 1:00 pm

    NORWELL, Mass. & MIAMI--(BUSINESS WIRE)--NORD and OpenEvidence launch AI-powered, expert-reviewed rare disease resources for clinicians and patients to accelerate diagnosis and informed care.

  • Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
    Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients12 March 2026, 12:00 pm

    JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

  • Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo
    Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo12 March 2026, 11:00 am

    MIAMI--(BUSINESS WIRE)-- #AIPoweredVisionDiagnostics--Heru, the leader in AI-powered vision diagnostics, announced it is showcasing the new PretestPro on its Heru wearable platform at Vision Expo 2026.

  • Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
    Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology12 March 2026, 11:00 am

    HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of T1N0M0 papillary thyroid microcarcinoma (PTM), a small, slow-growing, and most common form of thyroid cancer. The i

  • Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease
    Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease11 March 2026, 2:45 pm

    WALTHAM, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscle, metabolic and rare diseases, today announced the presentation of new preclinical data on the lead therapeutic in its bioenergetics restoration franchise, PX578, at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. PX578, a first-in-class small molecule activator of the mitochondrial DNA polymer

  • Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
    Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases11 March 2026, 12:00 pm

    TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

  • NASA Awards Redwire $4 Million In Additional Funding to Support Trailblazing Drug Development in Microgravity
    NASA Awards Redwire $4 Million In Additional Funding to Support Trailblazing Drug Development in Microgravity11 March 2026, 11:00 am

    JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwire’s Pharmaceutical In-space Laboratory (PIL-BOX) technology. This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract

  • Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic Dose in the First Phase of Its Clinical Trial
    Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic Dose in the First Phase of Its Clinical Trial11 March 2026, 9:30 am

    EVRY, France--(BUSINESS WIRE)--The selected dose in the pivotal phase is lower than for other drug candidates in clinical trials or gene therapy drugs for Duchenne.

  • Starfighters Partners with Mu-GTech for Microgravity Flights
    Starfighters Partners with Mu-GTech for Microgravity Flights10 March 2026, 12:00 pm

    CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world’s largest fleet of commercial supersonic aircraft, today announced a strategic partnership with Mu-G Technologies, LLC (“Mu-GTech”) to pursue microgravity flight missions for NASA, academic institutions and commercial research customers across the United States and Canada. The collaboration combines Starfighter

  • Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
    Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 202610 March 2026, 11:01 am

    DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 curre

  • NationsBenefits and Food City Partner to Expand Flex Card Access for Rx and OTC Health Needs Across Southeastern Communities
    NationsBenefits and Food City Partner to Expand Flex Card Access for Rx and OTC Health Needs Across Southeastern Communities10 March 2026, 11:00 am

    PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare benefits and fintech platform, today announced a new retail network integration with Food City, a trusted supermarket chain serving communities across Tennessee, Kentucky, Virginia, Georgia, and Alabama. Through this integration, eligible health plan members can use their NationsBenefits Mastercard® Prepaid Flex Card at all participating Food City locations to purchase approved food as medicine items, OTC health and wel

  • JECT Opens Its Ninth Location in West Palm Beach
    JECT Opens Its Ninth Location in West Palm Beach9 March 2026, 1:02 pm

    WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Leading medical aesthetics brand, JECT, has opened its newest location in West Palm Beach, FL.

No Feed

No Feed

No Feed

No Feed

No Feed